AstraZeneca Remains Committed to Partnering in China

AstraZeneca plans to continue an emphasis on partnership in China drug development, rather than outright acquisition of China biopharmas with promising technology, according to Steve Yang, PhD, AstraZeneca vice-president and head of R&D for Asia and emerging markets. "In China, our collaboration strategy is to forge partnership with leading academic and medical institutions that already have in-depth expertise in Asia-specific diseases," said Yang. More details.... Stock Symbol: (NYSE: AZN)     Share this with colleagues: